—
C+
C+ The full Closelook — membership. Open the C+ overview

Crinetics Pharmaceuticals Inc (CRNX) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Crinetics Pharmaceuticals Inc

CRNX in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Crinetics Pharmaceuticals is a clinical-stage biotech that researches and develops drugs for rare endocrine diseases and endocrine-related tumours. Its lead candidate, paltusotine, is an oral drug being tested for acromegaly and a related neuroendocrine-tumour syndrome, and the pipeline also includes candidates aimed at Cushing's disease, thyroid conditions, kidney disease and obesity. It is based in San Diego and has not yet brought a product to market.
Where it sits in the stack
Crinetics carries no seat in our index, so it sits simply within the Healthcare sector of our universe, in the Biotechnology sleeve alongside other clinical-stage drug developers. It is not a supplier or customer inside any hardware build-out; its position is that of a research-stage company whose value depends on trial outcomes and eventual regulatory approval rather than on shipments, orders or capacity.
Who it is priced against
Closelook's peer group here is scored healthcare names based in the US, gathered for that shared sector and country rather than for similar pipelines, and includes argenx, Vertex Pharmaceuticals and Regeneron among others. A name the market often mentions alongside it, given the overlapping obesity-drug ambitions, is Novo Nordisk.
Why Closelook tracks it
Crinetics carries a Closelook score with momentum the strongest of its seven modules and valuation the weakest; it holds no index seat and the diary has not yet quoted it directly.
What the diary watches
The diary watches trial readouts for paltusotine and the other pipeline candidates, since any shift in trial timing or outcome would be the main thing to change this read.

Crinetics Pharmaceuticals Inc (CRNX) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 49/100 composite (momentum 99, quality 21, valuation 4) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for CRNX, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against CRNX on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What CRNX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 none reported
  • Share count +16.4% in FY2025 91 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Crinetics Pharmaceuticals Inc (CRNX)?

Crinetics Pharmaceuticals Inc trades as CRNX on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is CRNX in a Closelook index?

Not currently — Crinetics Pharmaceuticals Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is Crinetics Pharmaceuticals Inc's Closelook composite score?

49 out of 100, with momentum 99, quality 21 and valuation 4 sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does CRNX trade against its moving averages?

Uptrend stack intact: Trades +10.6% vs the 50-day and +67% vs the 200-day average, 0.1% below the 52-week high and +163% off the 52-week low; a golden cross printed 35 sessions ago. Computed from daily closes. As of 2026-09-02 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Crinetics Pharmaceuticals Inc do?

Crinetics Pharmaceuticals is a clinical-stage biotech that researches and develops drugs for rare endocrine diseases and endocrine-related tumours. Its lead candidate, paltusotine, is an oral drug being tested for acromegaly and a related neuroendocrine-tumour syndrome, and the pipeline also includes candidates aimed at Cushing's disease, thyroid conditions, kidney disease and obesity. It is based in San Diego and has not yet brought a product to market. Closelook's peer group here is scored healthcare names based in the US, gathered for that shared sector and country rather than for similar pipelines, and includes argenx, Vertex Pharmaceuticals and Regeneron among others. A name the market often mentions alongside it, given the overlapping obesity-drug ambitions, is Novo Nordisk.

Where does Crinetics Pharmaceuticals Inc sit in the AI build-out?

Crinetics carries no seat in our index, so it sits simply within the Healthcare sector of our universe, in the Biotechnology sleeve alongside other clinical-stage drug developers. It is not a supplier or customer inside any hardware build-out; its position is that of a research-stage company whose value depends on trial outcomes and eventual regulatory approval rather than on shipments, orders or capacity. Crinetics carries a Closelook score with momentum the strongest of its seven modules and valuation the weakest; it holds no index seat and the diary has not yet quoted it directly.

Does Crinetics Pharmaceuticals Inc pay a dividend?

No cash distribution shows in Crinetics Pharmaceuticals Inc’s price series over the last three years. The share count rose 16.4% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for CRNX, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.